Prospective Study of oncRNA Stratification of Cancer by Size and Stage

Launched by EXAI BIO INC. · Apr 17, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new blood test that aims to detect cancer early by looking for specific markers in the blood called oncRNAs. These markers are usually present in higher amounts in people with cancer and very low in those without cancer. By using advanced technology like artificial intelligence, researchers hope to identify unique patterns of these markers that can help find different types of cancer, even in its earliest stages. The goal is to make cancer detection easier and more effective, potentially saving lives.

To participate in this study, individuals must be at least 18 years old and able to provide consent. They will need to give a small blood sample and share their medical history. The study is open to various groups, including people without cancer, those at risk for cancer, and individuals with existing cancer. Participants can expect to contribute to important research that could lead to a simple blood test for cancer detection in the future, which could change how we approach cancer diagnosis in America.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Able and willing to provide informed consent
• • Able and willing to have 35-40 mL of whole blood drawn
• Exclusion Criteria:
• • Age \<18 years
• • Prior history of cancer, except for non-melanoma skin cancer
• • Prior history of receipt of any blood products within 30 days of enrollment
• • Receipt of any cancer therapy, e.g., surgical, radiation, or medical including neoadjuvant treatment, prior to study enrollment
• • Prior history of receipt of any non-cancer system immune modulation therapy within the last 60 days (ex: monoclonal antibodies)
• • Prior history of organ transplantation
• • Current or prior pregnancy within the last 12 months
• • Unable or unwilling to provide informed consent